Markus Reschke

3.0k total citations
31 papers, 1.7k citations indexed

About

Markus Reschke is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Markus Reschke has authored 31 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 16 papers in Oncology and 7 papers in Immunology. Recurrent topics in Markus Reschke's work include Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (4 papers) and Immunotherapy and Immune Responses (4 papers). Markus Reschke is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (4 papers) and Immunotherapy and Immune Responses (4 papers). Markus Reschke collaborates with scholars based in Austria, Germany and United States. Markus Reschke's co-authors include Axel Ullrich, Erwin F. Wagner, Pjotr Knyazev, Pier Paolo Pandolfi, Markus Hutterer, Ingvar Ferby, Rainer Spanagel, Rolf Sprengel, Øivind Hvalby and Alexander Fleischmann and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Journal of Neuroscience.

In The Last Decade

Markus Reschke

30 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Markus Reschke Austria 16 938 542 358 226 195 31 1.7k
Yigong Fu United States 16 777 0.8× 375 0.7× 224 0.6× 160 0.7× 141 0.7× 23 1.4k
John F. Reilly United States 25 1.8k 1.9× 572 1.1× 264 0.7× 237 1.0× 287 1.5× 43 3.0k
Dara Kallop United States 13 1.2k 1.3× 579 1.1× 427 1.2× 126 0.6× 278 1.4× 13 2.1k
Lieve Umans Belgium 28 1.9k 2.0× 350 0.6× 176 0.5× 237 1.0× 285 1.5× 49 2.8k
Joseph H. McCarty United States 27 1.3k 1.4× 401 0.7× 302 0.8× 235 1.0× 404 2.1× 55 2.6k
Chris Shelley United States 22 953 1.0× 266 0.5× 315 0.9× 403 1.8× 281 1.4× 39 1.7k
Katerina Tritsaris Denmark 20 875 0.9× 581 1.1× 164 0.5× 200 0.9× 302 1.5× 32 1.7k
Su Yang China 26 1.4k 1.5× 550 1.0× 299 0.8× 70 0.3× 510 2.6× 93 2.4k
Pengcheng Zhou China 19 1.0k 1.1× 316 0.6× 131 0.4× 198 0.9× 139 0.7× 34 1.6k
Tatyana V. Taksir United States 17 1.0k 1.1× 336 0.6× 158 0.4× 337 1.5× 241 1.2× 24 1.9k

Countries citing papers authored by Markus Reschke

Since Specialization
Citations

This map shows the geographic impact of Markus Reschke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Reschke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Reschke more than expected).

Fields of papers citing papers by Markus Reschke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Reschke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Reschke. The network helps show where Markus Reschke may publish in the future.

Co-authorship network of co-authors of Markus Reschke

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Reschke. A scholar is included among the top collaborators of Markus Reschke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Reschke. Markus Reschke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Reschke, Markus, Frederik H. Igney, Peter Maier, et al.. (2022). Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96. Biomedicines. 10(9). 2146–2146. 2 indexed citations
2.
Niewoehner, Ole, Gráinne Kerr, Scott Gleim, et al.. (2020). Identification of the HECT E3 ligase UBR5 as a regulator of MYC degradation using a CRISPR/Cas9 screen. Scientific Reports. 10(1). 20044–20044. 14 indexed citations
3.
Sykora, Martina M. & Markus Reschke. (2019). Immunophenotyping of Tissue Samples Using Multicolor Flow Cytometry. Methods in molecular biology. 1953. 253–268. 1 indexed citations
4.
Bezzi, Marco, Nina Seitzer, T. Ishikawa, et al.. (2018). Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. Nature Medicine. 24(2). 165–175. 134 indexed citations
5.
Hilberg, Frank, Markus Reschke, Marco H. Hofmann, & Norbert Kraut. (2017). P2.01-045 Nintedanib Improves Anti-Tumor Efficacy in Combination with Anti PD-1 in Syngeneic Tumor Models Sensitive and Refractory to IO Inhibition. Journal of Thoracic Oncology. 12(1). S813–S813. 4 indexed citations
6.
Reschke, Markus, Ulrich Reiser, Dirk Scharn, et al.. (2017). Abstract 2330: BI5: a novel SMAC mimetic that triggers tumor cell death and potentiates PD-1 mediated cancer therapy. Cancer Research. 77(13_Supplement). 2330–2330.
7.
Rudolph, Dorothea, Claudia Blaukopf, Christoph Sommer, et al.. (2015). Efficacy and Mechanism of Action of Volasertib, a Potent and Selective Inhibitor of Polo-Like Kinases, in Preclinical Models of Acute Myeloid Leukemia. Journal of Pharmacology and Experimental Therapeutics. 352(3). 579–589. 50 indexed citations
8.
Kats, Lev M., Markus Reschke, Riccardo Taulli, et al.. (2014). Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance. Cell stem cell. 14(3). 329–341. 146 indexed citations
9.
Fagoonee, Sharmila, Claudia Bearzi, Ferdinando Di Cunto, et al.. (2013). The RNA Binding Protein ESRP1 Fine-Tunes the Expression of Pluripotency-Related Factors in Mouse Embryonic Stem Cells. PLoS ONE. 8(8). e72300–e72300. 36 indexed citations
10.
Reschke, Markus, John G. Clohessy, Nina Seitzer, et al.. (2013). Characterization and Analysis of the Composition and Dynamics of the Mammalian Riboproteome. Cell Reports. 4(6). 1276–1287. 42 indexed citations
11.
Rau, Rachel E., Daniel Magoon, Sarah Greenblatt, et al.. (2013). NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease. Experimental Hematology. 42(2). 101–113.e5. 27 indexed citations
12.
Clohessy, John G., Markus Reschke, & Pier Paolo Pandolfi. (2012). Found in translation of mTOR signaling. Cell Research. 22(9). 1315–1318. 12 indexed citations
13.
Reschke, Markus, et al.. (2011). Context awareness through the RF-channel. 347. 7 indexed citations
14.
Bakiri, Latifa, Markus Reschke, Holly A. Gefroh, et al.. (2010). Functions of Fos phosphorylation in bone homeostasis, cytokine response and tumourigenesis. Oncogene. 30(13). 1506–1517. 15 indexed citations
15.
Descot, Arnaud, Reinhard Hoffmann, Dmitry Shaposhnikov, et al.. (2009). Negative Regulation of the EGFR-MAPK Cascade by Actin-MAL-Mediated Mig6/Errfi-1 Induction. Molecular Cell. 35(3). 291–304. 82 indexed citations
16.
Reschke, Markus, Ingvar Ferby, Ewa Stępniak-Konieczna, et al.. (2009). Mitogen‐inducible gene‐6 is a negative regulator of epidermal growth factor receptor signaling in hepatocytes and human hepatocellular carcinoma†. Hepatology. 51(4). 1383–1390. 63 indexed citations
17.
Reschke, Markus, Daniela Mihic‐Probst, Edward H. van der Horst, et al.. (2008). HER3 Is a Determinant for Poor Prognosis in Melanoma. Clinical Cancer Research. 14(16). 5188–5197. 139 indexed citations
18.
Hutterer, Markus, Pjotr Knyazev, Markus Reschke, et al.. (2008). Axl and Growth Arrest–Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme. Clinical Cancer Research. 14(1). 130–138. 215 indexed citations
19.
Ferby, Ingvar, Markus Reschke, Oliver Kudlacek, et al.. (2006). Mig6 is a negative regulator of EGF receptor–mediated skin morphogenesis and tumor formation. Nature Medicine. 12(5). 568–573. 204 indexed citations
20.
David, Jean‐Pierre, Latifa Bakiri, Arndt F. Schilling, et al.. (2005). Essential role of RSK2 in c-Fos–dependent osteosarcoma development. Journal of Clinical Investigation. 115(3). 664–672. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yigong Fu Breakdown of academic impact, for papers by John F. Reilly Breakdown of academic impact, for papers by Dara Kallop Breakdown of academic impact, for papers by Lieve Umans Breakdown of academic impact, for papers by Joseph H. McCarty Breakdown of academic impact, for papers by Chris Shelley Breakdown of academic impact, for papers by Katerina Tritsaris Breakdown of academic impact, for papers by Su Yang Breakdown of academic impact, for papers by Pengcheng Zhou Breakdown of academic impact, for papers by Tatyana V. Taksir
Rankless by CCL
2026